IARS1: A Promising Drug Target for Cancer Treatment (G3376)

Target Name: IARS1

NCBI ID: G3376

IARS1

IARS1: A Promising Drug Target for Cancer Treatment

The International Agency for the Research of Cancer (IARC) has identified IARS1 (IARC-1) as a promising drug target for cancer treatment. IARS1 is a gene that is expressed in various tissues and has been linked to the development and progression of many types of cancer. The identification of IARS1 as a potential drug target has generated a lot of interest in the pharmaceutical industry and has the potential to lead to new and more effective cancer treatments.

IARS1 and Cancer

IARS1 has been shown to be involved in the development and progression of many types of cancer, including breast, ovarian, and prostate cancers. Studies have shown that high levels of IARS1 expression are associated with poor prognosis and increased risk of cancer recurrence. In addition, IARS1 has been shown to play a role in the development of cancer-induced stem cells, which can lead to the formation of tumors.

IARC has also identified IARS1 as a potential biomarker for cancer diagnosis and monitoring. The association between IARS1 and cancer has led to the development of new diagnostic tests and therapeutic approaches. For example, researchers have used IARS1 to develop a diagnostic test for breast cancer, which has the potential to identify women at risk of recurrence. In addition, IARS1 has also been used to develop new cancer therapies, including targeted therapies and immunotherapies.

The Potential of IARS1 as a Drug Target

IARS1 has the potential to be a drug target for cancer treatment due to its involvement in the development and progression of many types of cancer. The identification of IARS1 as a potential drug target has generated a lot of interest in the pharmaceutical industry, with many companies conducting research on IARS1 and its potential as a drug.

One of the main advantages of IARS1 as a drug target is its druggability. IARS1 has been shown to be involved in a wide range of cellular processes, including cell signaling, cell division, and cell adhesion. This makes it a potential target for drugs that can interfere with these processes and prevent cancer growth. In addition, IARS1 has a well-established expression profile, which has made it easier for researchers to identify potential drugs.

Another advantage of IARS1 as a drug target is its potential to be used in combination with other therapies. IARS1 has been shown to play a role in cancer-induced stem cell formation, which can lead to the formation of tumors. This means that IARS1 could be used in combination with therapies that target cancer stem cells, such as cancer vaccines or adoptive T cell therapy.

IARS1 has also been shown to be involved in the development of cancer-induced immune evasion, which is a major challenge in cancer treatment. cancer cells can manipulate the immune system to avoid detection and destruction by T cells. IARS1 has been shown to play a role in this process, which makes it a potential target for cancer immunotherapy.

IARC has identified IARS1 as a potential drug target for breast, ovarian, and prostate cancers. Studies have shown that targeting IARS1 using small molecules, antibodies, or other therapeutic agents can lead to the inhibition of cancer cell growth and the formation of tumors. In addition, IARS1 has also been shown to be involved in the development of cancer-induced stem cells, which can lead to the formation of tumors. This makes IARS1 a potential target for cancer vaccines, adoptive T cell therapy, and other therapies that target cancer stem cells.

Conclusion

IARS1 is a gene that has been linked to the development and progression of many types of cancer. The identification of IARS1 as a potential drug target has generated a lot of interest in the pharmaceutical industry and has the potential to lead to new and more effective cancer treatments. IARS1 has the potential to be used in combination with other therapies to target cancer stem cells and to inhibit cancer cell growth. Further research is needed to fully understand the role of IARS1 in cancer and to develop safe and effective treatments.

Protein Name: Isoleucyl-tRNA Synthetase 1

Functions: Catalyzes the specific attachment of an amino acid to its cognate tRNA in a 2 step reaction: the amino acid (AA) is first activated by ATP to form AA-AMP and then transferred to the acceptor end of the tRNA

The "IARS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IARS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets